MAP2K7 and melanoma: The advent of BRAF inhibitors (such as vemurafenib and dabrafenib) (Muñoz-Couselo et al., 2015)and their subsequent combination with MEK inhibitors (such as trametinib and cobimetinib) has significantly improved the prognosis for patients harboring BRAF-mutant melanoma (Bucheit and Davies, 2014; El-Nassan, 2014; Zhang, 2015).